MA27692A1 - Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments - Google Patents

Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments

Info

Publication number
MA27692A1
MA27692A1 MA27902A MA27902A MA27692A1 MA 27692 A1 MA27692 A1 MA 27692A1 MA 27902 A MA27902 A MA 27902A MA 27902 A MA27902 A MA 27902A MA 27692 A1 MA27692 A1 MA 27692A1
Authority
MA
Morocco
Prior art keywords
preparation
medicaments
benzoxazinone
compounds derived
compounds
Prior art date
Application number
MA27902A
Other languages
English (en)
Inventor
Jover Antoni Torrens
Castrillo Perez Jose Aurelio
Constansa Jordi Frigola
Prio Josep Mas
Zueras Alberto Dordal
Fisas Escasany Maria Angeles
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA27692A1 publication Critical patent/MA27692A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés dérivés de benzoxazinone de formule générale (I), des méthodes pour leur préparation, des médicaments comprenant ces composés, ainsi que leur utilisation dans la préparation d'un médicament destiné au traitement des êtres humains et des animaux.
MA27902A 2002-04-09 2004-10-08 Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments MA27692A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
MA27692A1 true MA27692A1 (fr) 2006-01-02

Family

ID=28686085

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27902A MA27692A1 (fr) 2002-04-09 2004-10-08 Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments

Country Status (29)

Country Link
US (3) US7056914B2 (fr)
EP (2) EP1497285B1 (fr)
JP (1) JP2005529866A (fr)
KR (1) KR20050008679A (fr)
CN (1) CN1659164A (fr)
AR (2) AR039256A1 (fr)
AT (2) ATE489382T1 (fr)
AU (2) AU2003222804A1 (fr)
BR (1) BR0309083A (fr)
CA (1) CA2481701A1 (fr)
DE (2) DE60335094D1 (fr)
DK (1) DK1500654T3 (fr)
EC (1) ECSP045353A (fr)
ES (3) ES2193875B2 (fr)
HK (1) HK1069820A1 (fr)
HR (1) HRP20040919A2 (fr)
IL (1) IL164442A0 (fr)
IS (1) IS7491A (fr)
MA (1) MA27692A1 (fr)
MX (1) MXPA04009889A (fr)
NO (1) NO20044322L (fr)
NZ (1) NZ536167A (fr)
PL (1) PL372537A1 (fr)
PT (1) PT1500654E (fr)
RU (1) RU2004133041A (fr)
TN (1) TNSN04203A1 (fr)
UA (1) UA79460C2 (fr)
WO (2) WO2003084952A1 (fr)
ZA (1) ZA200408275B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
WO2005090340A1 (fr) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. Dérivé de piperidine-1-carboxamide
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
JP2008523110A (ja) * 2005-03-21 2008-07-03 ザ プロクター アンド ギャンブル カンパニー 視覚的に区別できる相を含む多相パーソナルケア組成物
EP1874408A1 (fr) * 2005-04-13 2008-01-09 The Procter and Gamble Company Compositions de nettoyage pour l'hygiene personnelle douces, structurees et multiphasees
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101326106A (zh) * 2005-12-08 2008-12-17 宝洁公司 包括邻近表面形貌定位的模内标签的容器
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
EP2061795B1 (fr) * 2006-08-14 2014-01-15 Council of Scientific & Industrial Research Hybrides pyrrolo[2,1-c][1,4]benzodiazépine et leur procédé de préparation
EP1902733A1 (fr) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combinaison de substances actives comporant un ligand de récepteur NMDA et un composé a affinité de récepteur 5-HT6
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
EP2404902A1 (fr) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216580T1 (de) * 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
JPH09512016A (ja) 1994-04-14 1997-12-02 メルク エンド カンパニー インコーポレーテッド α１Ｃアドレナリン受容体拮抗薬
WO1997019682A1 (fr) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Derives aryle sulfonamide et sulfamide, et leurs utilisations
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997025992A1 (fr) 1996-01-16 1997-07-24 Merck & Co., Inc. Antagonistes des recepteurs de l'oxytocine tocolytique
WO1997038665A2 (fr) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
WO1998024768A1 (fr) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Nouveaux derives d'uree
EP0910565A1 (fr) 1997-02-14 1999-04-28 Bayer Corporation Derives amides actifs comme antagonistes selectifs du recepteur du neuropeptide y
WO1998040356A1 (fr) 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
WO2001007409A1 (fr) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Derives de carbazole et leur utilisation en tant que ligands du recepteur de neuropeptide y5
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
MXPA04001144A (es) * 2001-08-07 2004-07-08 Banyu Pharma Co Ltd Compuestos espiro.
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
NO20044322L (no) 2004-10-12
AU2003222804A1 (en) 2003-10-20
ATE489382T1 (de) 2010-12-15
PT1500654E (pt) 2006-06-30
ATE316966T1 (de) 2006-02-15
US7041665B2 (en) 2006-05-09
AR048567A1 (es) 2006-05-10
JP2005529866A (ja) 2005-10-06
ECSP045353A (es) 2005-01-28
CA2481701A1 (fr) 2003-10-16
ES2193875A1 (es) 2003-11-01
AR039256A1 (es) 2005-02-16
BR0309083A (pt) 2005-04-19
ES2258219T3 (es) 2006-08-16
PL372537A1 (en) 2005-07-25
DE60335094D1 (de) 2011-01-05
CN1659164A (zh) 2005-08-24
DE60303440T2 (de) 2006-10-26
TNSN04203A1 (en) 2007-03-12
IS7491A (is) 2004-10-06
MXPA04009889A (es) 2005-08-16
KR20050008679A (ko) 2005-01-21
NZ536167A (en) 2006-06-30
IL164442A0 (en) 2005-12-18
US7514429B2 (en) 2009-04-07
US20040067941A1 (en) 2004-04-08
UA79460C2 (en) 2007-06-25
ES2356815T3 (es) 2011-04-13
HK1069820A1 (en) 2005-06-03
ZA200408275B (en) 2006-04-26
HRP20040919A2 (en) 2005-04-30
US7056914B2 (en) 2006-06-06
DK1500654T3 (da) 2006-06-06
EP1497285B1 (fr) 2010-11-24
EP1500654B1 (fr) 2006-02-01
ES2193875B2 (es) 2005-03-01
RU2004133041A (ru) 2005-09-10
EP1497285A1 (fr) 2005-01-19
US20040058920A1 (en) 2004-03-25
AU2003216934A1 (en) 2003-10-20
DE60303440D1 (de) 2006-04-13
EP1500654A1 (fr) 2005-01-26
US20060128701A1 (en) 2006-06-15
WO2003084939A1 (fr) 2003-10-16
WO2003084952A1 (fr) 2003-10-16

Similar Documents

Publication Publication Date Title
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
TNSN04164A1 (fr) Inhibiteurs de acc.
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA27573A1 (fr) Sinomenine et derives de sinomenine, synthese et utilisation.
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA30514B1 (fr) Nouveaux composes.
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
EP2289891A3 (fr) Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA33420B1 (fr) Dérivés fluorés de l'aminotriazole
MA30406B1 (fr) Nouveaux composes
MA24729A1 (fr) Macrolides nouveaux.
MA34308B1 (fr) Triazolopyridines substituées
MA27629A1 (fr) Dérivés du benzènesulfonamide, leur procédé de préparation et leur utilisation pour le traitement de la douleur.